๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Changsha
Clinical trial register · China

Clinical Trials in Changsha, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca136 Xiangya Hospital of Central South University49 Eli Lilly and Company36 Second Xiangya Hospital of Central South University36 Hunan Province Tumor Hospital32
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Changsha

1154 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Hohhot
2025-08-06
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Beijing, Changchun, Changsha, Chongqing, Guangzhou, Hangzhou, Jinan, Jinhua
2025-08-06
Recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
NCT07038382Membranous Nephropathy, Lupus Nephritis (LN)
Shanghai Henlius Biotech
Phase 2
24
Beijing, Changsha, Guangzhou, Hangzhou, Hefei, Luoyang, Nanchang, Nanjing
2025-08-05
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
Pfizer
Phase 3
400
Hefei, Fuzhou, Guangzhou, Baoding, Wuhan, Changsha, Nanjing, Dalian
2025-08-05
Recruiting
A Study of YL202 in Patients With Advanced Solid Tumors
NCT07202364Non Small Cell Lung Cancer, Colorectal Cancer, Cervical Cancer, Locally Advanced or Metastatic Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Changsha
2025-08-04
Recruiting
Preliminary Clinical Study on the Effect of Bacillus Subtilis on the Efficacy of Infliximab in Patients With Crohn's Disease
NCT07123207Mild to Severe Crohns Disease
The Third Xiangya Hospital of Central South University
Not applicable
24
Changsha
2025-08-04
Recruiting
Real World Evidence Study of SYN023 in Children Exposed to Rabies
NCT07327307Rabies Post-exposure Prophylaxis
Synermore Biologics (Suzhou) Co., Ltd.
Observational
232
Beijing, Shenzhen, Changsha, Hengyang, Nanchang
2025-08-02
Recruiting
Assessment of DOT Spectacles in Chinese Children Extension
NCT07008001Juvenile Myopia, Myopia
SightGlass Vision, Inc.
Not applicable
175
Changsha, Chengdu, Guangzhou, Shanghai, Tianjin
2025-08-01
Recruiting
The Impact of Transjugular Intrahepatic Portosystemic Shunt on Recompensation in Patients With Decompensated Liver Cirrhosis
NCT07172035Cirrhosis, Decompensation, Transjugular Intrahepatic Portosystemic Shunt (TIPS), Survival Analysis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
250
Changsha, Fuzhou, Huanggang, Jingzhou, Nanchang, Nanjing, Shenyang, Taiyuan
2025-08-01
Not yet open
Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
NCT07023575Interstitial Lung Abnormalities
China-Japan Friendship Hospital
Observational
100,000
Beijing, Shanghai, Changsha, Guiyang, Hangzhou, Henan, Qingdao, Shenyang
2025-08-01
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
AstraZeneca
Phase 3
800
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou
2025-08-01
Not yet open
the Efficacy and Safety of Oliceridine Fumarate Injection for Acute Pain After Abdominal Surgery
NCT06530563Acute Pain, Opioid Analgesic Adverse Reaction
Xiangya Hospital of Central South University
Phase 4
606
Changsha
2025-08
Not yet open
Evaluate the Long-term Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
NCT07133815Homozygous Familial Hypercholesterolemia
Beijing Suncadia Pharmaceuticals Co., Ltd
Phase 2
55
Changsha
2025-08
Recruiting
A Clinical Study of GO306 in Patients With Advanced Solid Tumors
NCT07128914Solid Tumor Malignancies
GeneSail Biotech (Shanghai) Co., Ltd.
Phase 1
32
Hefei, Fuzhou, Shenzhen, Zhengzhou, Changsha, Shanghai
2025-07-31
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
Pfizer
Phase 3
208
Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Chengdu, Kunming, Hangzhou
2025-07-31
Not yet open
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326NSCLC, Neoadjuvant Therapy, Immunotherapy, AK112
Yang Fan, MD
Phase 2
164
Beijing, Changsha, Shanghai, Xiโ€™an, Hangzhou
2025-07-31
Recruiting
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
NCT07124936Diffuse Large B Cell Lymphoma (DLBCL)
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1/2
97
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan, Changsha
2025-07-30
Recruiting
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
NCT07079475Non-Small Cell Lung Cancer
Dizal Pharmaceuticals
Phase 1/2
220
Beijing, Guangzhou, Harbin, Changsha, Nanjing, Changchun, Shengyang, Jinan
2025-07-30
Recruiting
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
NCT07061535Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer, Extensive Disease Small Cell Lung Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2
40
Changsha, Jinan, Hangzhou
2025-07-30
Recruiting
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
NCT06911502Follicular Lymphoma
Celgene
Phase 3
400
Beijing, Fuzhou Fujian, Guangzhou, Harbin, Wuhan, Changsha, Hohhot, Suzhou
2025-07-28
Recruiting
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
NCT07071519Ulcerative Colitis
AbbVie
Phase 3
120
Guangzhou, Zhengzhou, Changsha, Changchun, Shanghai, Hangzhou
2025-07-28
Recruiting
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
ArriVent BioPharma, Inc.
Phase 1
572
Beijing, Chongqing, Zhejiang, Heilongjiang, Zhengzhou, Wuhan, Changsha, Shandong
2025-07-25
Recruiting
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268Eczema
Pfizer
Phase 3
150
Beijing, Shenzhen, Changsha, Nanchang, Shanghai, Hangzhou
2025-07-24
Recruiting
A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer
NCT07024173Locally Advanced Breast Cancer, Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 3
240
Guangzhou, Changsha
2025-07-23
Recruiting
EASi-PROTKTโ„ข - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473Diabetes Mellitus, Type 2, Hypertension, Cardiovascular Diseases
Boehringer Ingelheim
Phase 3
11,800
Baotou, Beijing, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Dalian
2025-07-22
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
NCT07005713Chronic Spontaneous Urticaria
BeOne Medicines
Phase 1
58
Beijing, Chongqing, Guangzhou, Wuhan, Changsha, Qingdao, Chengdu, Hangzhou
2025-07-19
Recruiting
A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
NCT06929273Bipolar Disorder Type I With Mania
Bristol-Myers Squibb
Phase 3
450
Beijing, Guangzhou, Baoding, Changsha, Nanjing, Xi'an, Chengdu, Tianjin
2025-07-18
Recruiting
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089Solid Tumors
DualityBio Inc.
Phase 2
450
Beijing, Dongguan, Henan, Xinxiang, Hubei, Wuhan, Changsha, Xuzhou
2025-07-18
Recruiting
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
NCT07043751Advanced Malignant Tumors
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
216
Beijing, Dongguan, Guangdong, Guangzhou, Anyang, Zhengzhou, Wuhan, Changsha
2025-07-15
Recruiting
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
NCT06963827Kidney Disease
Takeda
Phase 3
347
Beijing, Changping, Xiamen, Guangzhou, Shenzhen, Changsha, Baotou, Nanjing
2025-07-15
Recruiting
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
NCT06953323Advanced Solid Tumor
Wigen Biomedicine Technology (Shanghai) Co., Ltd.
Phase 1/2
86
Beijing, Fuzhou, Guangzhou, Nanning, Wuhan, Changsha, Shenyang, Hangzhou
2025-07-10
By invitation
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
NCT06882876Hepatocellular Carcinoma (HCC)
Xiangya Hospital of Central South University
Phase 1
20
Changsha
2025-07-10
Recruiting
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
NCT07011732Alzheimer Disease
Bristol-Myers Squibb
Phase 3
426
Beijing, Haidian District, Chongqing, Guangzhou, Shenzhen, Changsha, Nanjing, Shanghai
2025-07-10
Recruiting
Manual Thrombus Aspiration During PCI in STEMI With Angiographically Evident Thrombus
NCT06654453ST-segment Elevation Myocardial Infarction
Shenghua Zhou
Not applicable
3,500
Changsha
2025-07-09
Recruiting
Study of XNW28012 in Subjects With Metastatic Pancreatic Cancer Who Received Prior Systemic Therapy
NCT07823049Pancreatic Cancer
Evopoint Biosciences Inc.
Phase 3
226
Shanghai, Beijing, Binzhou, Changsha, Changzhou, Chengdu, Chongqing, Fuyang
2025-07-08
Active, closed
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis
NCT07483450Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Hoffmann-La Roche
Phase 4
60
Nanchang, Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hohhot
2025-07-04
Recruiting
TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
NCT07052903Transthyretin Amyloidosis With Cardiomyopathy
Alnylam Pharmaceuticals
Phase 3
1,750
Binhai, Changsha, Chengdu, Dongcheng, Fuzhou, Guangzhou, Haidian, Hangzhou
2025-07-02
Recruiting
Metformin Alleviates Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients
NCT07045142Schizophrenia
Central South University
Phase 3
400
Zhumadian, Changsha, Yueyang, Dali, Xiangshan
2025-07-01
Recruiting
Rectal NSAIDs With/Without PD Stent for PEP Prevention
NCT07117318Post-ERCP Acute Pancreatitis, Non-steroid Anti-inflammatory Drugs, Pancreatic Duct Stent Placement
Air Force Military Medical University, China
Not applicable
1,278
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Xi'an
2025-07-01
Not yet open
BR Combined With OR in Treatment-naรฏve Marginal Zone Lymphoma
NCT07008053Marginal Zone Lymphomas
Tianjin Medical University Cancer Institute and Hospital
Phase 2
37
Fuzhou, Shijiazhuang, Changsha, Jinan, Qingdao, Tianjin
2025-07
Not yet open
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
NCT07038460Resectable Non-small Cell Lung Cancer
Wen-zhao ZHONG
Phase 2
134
Guangzhou, Changsha, Hangzhou
2025-07
Recruiting
A Phase โ…ก Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
NCT06962865Non-Small Cell Lung Cancer
RemeGen Co., Ltd.
Phase 2
80
Beijing, Binzhou, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou
2025-06-30
Recruiting
A Study of DC50292A Tablet in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors
NCT07071090Solid Tumor Malignancies
Heronova Pharmaceuticals
Phase 1
32
Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Changsha, Jinan, Hangzhou
2025-06-30
Recruiting
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
NCT07082738Chronic Obstructive Pulmonary Disease (COPD)
AstraZeneca
Phase 2
987
Baotou, Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou
2025-06-27
Recruiting
Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial
NCT07103382Obesity
Second Xiangya Hospital of Central South University
Not applicable
40
Changsha
2025-06-26
Recruiting
Hybrid Closed-Loop for Perioperative Glycemic Control in T2DM With Parenteral Nutrition
NCT07121504Type 2 Diabetes
Second Xiangya Hospital of Central South University
Not applicable
40
Changsha
2025-06-26
Active, closed
Hyperkalemia Quality Improvement Program (HK-QIP) Study
NCT06884267Hyperkalemia
AstraZeneca
Not applicable
1,000
Beijing, Benxi, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuyang
2025-06-25
Recruiting
Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial
NCT07070479Recurrent or Metastatic Nasopharyngeal Carcinoma
Ming-Yuan Chen
Phase 2
208
Guangzhou, Zhongshan, Zhuhai, Changsha
2025-06-24
Recruiting
Acupuncture Combined With PD-1/PD-L1 Inhibitors for Advanced Lung Cancer
NCT06926140Lung Cancers
Guang'anmen Hospital of China Academy of Chinese Medical Sciences
Not applicable
240
Hefei, Beijing, Changsha
2025-06-21
Recruiting
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
NCT06959095Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 3
981
Changsha, Chengdu, Guangzhou, Hangzhou, Jiangmen, Jiangxi, Mianyang, Qingyuan
2025-06-20
Recruiting
A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF)
NCT06991257Heart Failure
Pfizer
Phase 2
620
Beijing, Lanzhou, Guangzhou, Haikou, Shijiazhuang, Changsha, Changchun, Xi'an
2025-06-19
Recruiting
The Application of "HUAXI Hole 1" in Reverse-sequence Endoscopic Nipple-sparing Mastectomy With Direct-to-implant Breast Reconstruction
NCT06995118Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Du Zhenggui
Not applicable
337
Fuzhou, Guangzhou, Anyang, Zhengzhou, Changsha, Hohhot, Suzhou, Nanchang
2025-06-17
Active, closed
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744Ulcerative Colitis
AbbVie
Phase 3
573
Hefei, Beijing, Chongqing, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Changsha
2025-06-17
Recruiting
IUS Predicts Guselkumab Efficacy in Patients With Moderate to Severe Crohn's Disease๏ผša Prospective Study
NCT07034664Crohn's Disease, Guselkumab, Intestinal Ultrasound, Predictor
The Third Xiangya Hospital of Central South University
Observational
50
Changsha
2025-06-16
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Recruiting
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
NCT06951711Bipolar Disorder Type I With Mania or Mania With Mixed Features
Bristol-Myers Squibb
Phase 3
274
Beijing, Wuhan, Changsha, Jining Shi, Tianjin
2025-06-13
Active, closed
Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
NCT06956235Hidradenitis Suppurativa
Merck Sharp & Dohme LLC
Phase 2
149
Guangzhou, Changsha, Changchun, Shanghai, รœrรผmqi, Hangzhou
2025-06-09
Active, closed
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
NCT06993116Advanced Solid Tumor
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 1
15
Fuzhou, Changsha
2025-06-09
Recruiting
The AIRTIVITYโ„ข Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Active, closed
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
NCT06786338IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN
Suzhou Sanegene Bio Inc.
Phase 2
45
Beijing, Changsha, Chengdu, Guiyang, Hangzhou, Shanghai, Yangzhou, Yinchuan
2025-06-06
Recruiting
First-in-Human Single and Multiple Dose of KLA578-1 for Injection
NCT07143318Healthy Volunteers
Hunan Kelun Pharmaceutical Co., Ltd.
Phase 1
48
Changsha
2025-06-05
Recruiting
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
NCT07000357Cardiovascular Disease
AstraZeneca
Phase 3
15,100
Anqing, Anyang, Baotou, Beijing, Bozhou, Changchun, Changde, Changsha
2025-06-04
Recruiting
A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease
NCT06958536Crohn's Disease
Sanofi
Phase 2
99
Changsha, Changzhou, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang
2025-06-03
Recruiting
Xiangya Cardiopulmonary Health and Disease Cohort
NCT06972784Respiratory Function Tests๏ผŒHeart Function Tests, Cardiopulmonary Function
Xiangya Hospital of Central South University
Observational
30,000
Changsha
2025-06-01
Recruiting
Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study
NCT07093294Crohn Disease (CD), Vedolizumab, Intestinal Ultrasound, Predictor
The Third Xiangya Hospital of Central South University
Observational
60
Changsha
2025-06-01
Recruiting
Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease
NCT07267117Heart Valve Disease, Mitral Valve (MV) Regurgitation, Mitral Valve Disease, Mitral Valve Stenosis
Second Affiliated Hospital, Zhejiang University, School of Medicine
Observational
10,000
Fuzhou, Wuhan, Changsha, Shenyang, Xi'an, Qingdao, Chengdu, รœrรผmqi
2025-06-01
Recruiting
A Multicenter, Prospective, Randomized, Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on the Natural Pregnancy Outcomes in Patients With Non-recurrent Spontaneous Abortion
NCT07039097Infertility and Miscarriage
The Third Xiangya Hospital of Central South University
Not applicable
418
Changsha
2025-06-01
Recruiting
A Multicenter, Prospective, Randomized Controlled Clinical Study on the Effect of Hysteroscopic Uterine Septum Resection on IVF-ET Outcomes in Infertile Patients With Non-recurrent Miscarriage
NCT07611656Infertility and Miscarriage
The Third Xiangya Hospital of Central South University
Not applicable
236
Changsha
2025-06-01
Recruiting
Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
NCT07063901Esophagus Cancer
Central South University
Observational
200
Changsha
2025-06-01
Recruiting
Indomethacin vs Diclofenac for Preventing PEP
NCT07071441ERCP, Pancreatitis, Non-steroidal Anti-inflammatory (NSAID), Indomethacin
Air Force Military Medical University, China
Not applicable
4,050
Beijing, Chongqing, Xiamen, Harbin, Kaifeng, Wuhan, Changsha, Jilin City
2025-06-01
Recruiting
Staging Strategies and Their Association With Prognosis and Therapy in Lung Cancer With Cystic Airspaces
NCT07066813Lung Cancer Associated With Cystic Airspaces
Central South University
Observational
500
Changsha
2025-06-01
Recruiting
Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury
NCT06947135Acute Myocardial Infarction
The Second Hospital of Anhui Medical University
Not applicable
166
Hefei, Changsha
2025-05-29
Recruiting
Evaluation of GM101 Injection in Patients With Parkinson's Disease
NCT07100171Parkinson's Disease
Genemagic Biosciences Co., Ltd
Phase EARLY_PHASE1
10
Changsha
2025-05-29
Recruiting
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
NCT06954467Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT07050459Locally Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
220
Beijing, Haerbin, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Chengdu
2025-05-20
Recruiting
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
NCT06935370Heart Failure
Boehringer Ingelheim
Phase 3
4,200
Beijing, Changchun, Changde, Changsha, Chengdu, Chenzhou, Chongqing, Dalian
2025-05-20
Recruiting
Establishment of Diagnosis and Classification System for Lung Interstitial and Airway Diseases (LIAD)
NCT06987266Interstitial Lung Diseases (ILD), Airway Disease
Xiangya Hospital of Central South University
Observational
900
Changsha
2025-05-20
Recruiting
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993Atopic Dermatitis
Novartis Pharmaceuticals
Phase 2
224
Guangzhou, Shantou, Changsha, Changchun, Hangzhou, Beijing, Shanghai
2025-05-16
Recruiting
A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data
NCT07126821Brain (Nervous System) Cancers, Brain Arterial Disease, Neuro-Degenerative Disease, Brain Tumors
Xiangya Hospital of Central South University
Observational
100,000
Changsha
2025-05-15
Recruiting
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer
NCT06957886HER2-low Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
566
Guangzhou, Changsha
2025-05-15
Recruiting
A Study of DXC008 in Patients With Prostate Cancer and Other Solid Tumors
NCT06926283Prostate Cancer, Other Solid Tumors, Ewing Sarcoma
Hangzhou DAC Biotechnology Co., Ltd.
Phase 1
110
Changsha, Hangzhou, Beijing
2025-05-15
Active, closed
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery
NCT06890533Pain
Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
Phase 3
560
Cangzhou, Changde, Changsha, Chengdu, Chongqing, Chโ€™ang-chโ€™un, Dalian, Deyang
2025-05-14
Recruiting
A Study of ZL-1310 in Participants With Selected Solid Tumors
NCT06885281Solid Tumors
Zai Lab (Shanghai) Co., Ltd.
Phase 1/2
166
Beijing, Xiamen, Guangzhou, Harbin, Changsha, Changchun, Shanghai
2025-05-12
Active, closed
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)
NCT06925750Pulmonary Arterial Hypertension
Merck Sharp & Dohme LLC
Phase 2
130
Guangzhou, Changsha, Shanghai, Kunming
2025-05-12
Active, closed
Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole
NCT06937476Major Depressive Disorder (MDD), Rumination
Central South University
Not applicable
108
Changsha
2025-05-08
Recruiting
Crisugabalin for Radiotherapy-Related Neuropathic Pain
NCT06766916Neuropathic Pain
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
172
Fuzhou, Guangzhou, Zhongshan, Nanning, Zhengzhou, Changsha
2025-05-07
Recruiting
Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
NCT06921785Hepatocellular Carcinoma
AstraZeneca
Phase 3
1,220
Beijing, Changchun, Changsha, Chengdu, Chifeng, Chongqing, Deyang, Fuzhou
2025-05-06
Recruiting
Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads
NCT06947356Hepatitis B
Guangzhou 8th People's Hospital
Not applicable
210
Guangzhou, Shenzhen, Shijiazhuang, Changsha, Wenzhou, Beijing
2025-05-03
Not yet open
Clinical Study of Nanocrystalline Megestrol in Malnourished Patients With First-Line Non-Small Cell Lung Cancer
NCT06828757Non Small Cell Lung Cancer
Hunan Province Tumor Hospital
Phase 3
94
Changsha
2025-05-01
Recruiting
Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
NCT07098026Gastric Cancer, Adenocarcinoma
Hunan Cancer Hospital
Not applicable
286
Changsha
2025-05-01
Recruiting
Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces
NCT07820423Lung Cancer Associated With Cystic Airspaces
Central South University
Observational
600
Changsha
2025-05-01
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
NCT06862869Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Observational
800
Zhanjiang, Guangzhou, Kaifeng, Zhengzhou, รœrรผmqi, Beijing, Changsha, Changzhou
2025-04-30
Recruiting
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection to Treat Moderate to Severe Glabellar Lines
NCT06937944Moderate to Severe Glabellar Lines
JHM BioPharma (Tonghua) Co. , Ltd.
Phase 3
669
Beijing, Chongqing, Guangzhou, Shijiazhuang, Changsha, Xuzhou, Shanghai, Xianyang
2025-04-30
Recruiting
Study on the Aortic Arch Single Branch Stent Graft System
NCT06915545Aortic Dissection
Lifetech Scientific (Shenzhen) Co., Ltd.
Not applicable
135
Changsha
2025-04-30
Recruiting
Blended Unified Protocol in Chinese Adolescents With Non-Suicidal Self-Injury
NCT06858540Non-suicidal Self-injury (NSSI)
Jian-Jun Ou
Not applicable
12
Changsha
2025-04-29
Recruiting
Skin Type Determination Using Image Artificial Intelligence
NCT07765303Skin Ageing, Skin
Region Skane
Observational
1,500
Changsha
2025-04-28
Recruiting
Clinical Study on the Effectiveness and Safety of Succinylated Gelatin Electrolyte Sodium Acetate Injection
NCT06977750Acute Normovolemic Hemodilution
Nanjing Chia-tai Tianqing Pharmaceutical
Not applicable
104
Changsha
2025-04-27
Recruiting
IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
NCT06974812Unresectable Locally Advanced or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2
250
Fuzhou, Changsha, Shanghai
2025-04-18
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
NCT06868277Carcinoma, Non-Small Cell Lung
AstraZeneca
Phase 3
830
Baoding, Beijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou
2025-04-10
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693Breast Cancer
Hoffmann-La Roche
Phase 3
450
Xiangyang, Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jiangmen
2025-04-09
Rows per page Showing 301–400 of 1154
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/changsha?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 1,154 of those studies with a site in Changsha.

How many clinical trials are recruiting in Changsha?

670 of the 1,154 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 112 have not yet opened recruitment, 352 are active but closed to new participants, and 20 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.